| 000 | 01643 a2200445 4500 | ||
|---|---|---|---|
| 005 | 20250515222047.0 | ||
| 264 | 0 | _c20100728 | |
| 008 | 201007s 0 0 eng d | ||
| 022 | _a1558-822X | ||
| 024 | 7 |
_a10.1007/s11899-009-0041-2 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aVarghese, Abraham M | |
| 245 | 0 | 0 |
_aEradicating minimal residual disease in chronic lymphocytic leukemia: should this be the goal of treatment? _h[electronic resource] |
| 260 |
_bCurrent hematologic malignancy reports _cJan 2010 |
||
| 300 |
_a35-44 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Review | ||
| 650 | 0 | 4 |
_aAntibodies, Monoclonal _xadministration & dosage |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aBiomarkers, Tumor _xblood |
| 650 | 0 | 4 | _aBone Marrow Examination |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aCombined Modality Therapy |
| 650 | 0 | 4 | _aDisease Management |
| 650 | 0 | 4 | _aFlow Cytometry |
| 650 | 0 | 4 | _aGoals |
| 650 | 0 | 4 | _aHematopoietic Stem Cell Transplantation |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aLeukemia, Lymphocytic, Chronic, B-Cell _xdrug therapy |
| 650 | 0 | 4 | _aMulticenter Studies as Topic |
| 650 | 0 | 4 | _aNeoplasm, Residual |
| 650 | 0 | 4 | _aPolymerase Chain Reaction |
| 650 | 0 | 4 | _aPrognosis |
| 650 | 0 | 4 | _aRemission Induction |
| 650 | 0 | 4 | _aSalvage Therapy |
| 650 | 0 | 4 | _aSurvival Analysis |
| 700 | 1 | _aRawstron, Andy C | |
| 700 | 1 | _aHillmen, Peter | |
| 773 | 0 |
_tCurrent hematologic malignancy reports _gvol. 5 _gno. 1 _gp. 35-44 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1007/s11899-009-0041-2 _zAvailable from publisher's website |
| 999 |
_c19782292 _d19782292 |
||